The new guidelines, published in the Journal of the American Academy of Dermatology (JAAD), will guide dermatologists in deciding the best possible prevention and treatment options for pediatric ...

Quality of life outcomes were examined based on the presence and severity of hand eczema among patients with atopic dermatitis.

In patients with moderate atopic dermatitis, the use of Opzelura (ruxolitinib) led to early and sustained improvements in ...

In this video, Kristin Sokol, MD, MPH, FAAAAI, FACAAI, discusses the role of the allergist in managing patients with chronic itch and/or atopic dermatitis.

Among patients with AD, GLP-1 RAs reduced the risk for various MACE outcomes, including heart failure, cerebrovascular disease, and more.

In this video, Kristin Sokol, MD, MPH, FAAAAI, FACAAI, discusses the impact of atopic dermatitis on patients' quality of life.

Patients with atopic dermatitis who receive treatment with dupilumab may be at an increased risk for new-onset vitiligo.

As the 2026 American Academy of Dermatology (AAD) annual meeting continues in Denver, MedPage Today is offering another ...

Historically good results with IL-4 inhibitors raise questions with U.S. audience ...

Atopic dermatitis (AD), also known as atopic eczema, is a chronic relapsing inflammatory skin condition. Incidence of AD has increased 2- to 3-fold in industrialized nations, impacting approximately ...

There is no cure for atopic dermatitis, the most common form of eczema. Instead, treatment can help reduce symptoms and establish long-lasting disease control. While atopic dermatitis treatment plans ...

Lebrikizumab maintained skin clearance and safety over three years in moderate to severe atopic dermatitis patients, with minimal need for rescue therapy. High long-term response rates were observed ...